Categoría

ACE/ACU

Home > Tipos de Proyecto > ACE/ACU (Page 7)

Navarro F, Martinez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, Gómez S, de Andrés-Nogales F, Casado MA, Oyagüez I

 

 

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
Clin Reumatol 2020;39:2919-30

García F, Domínguez-Hernández R, Casado M, Macías J, Téllez F, Pascasio JM, Casado MÁ, Alados JC

 

 

La simplificación del proceso de diagnóstico de la hepatitis C crónica es una estrategia coste-efectiva
Enfermedades Infecciosas y Microbiología Clínica 2019; 37(10): 634-641

Sierra J, Briones J, Calleja MA, Camacho C, Casado MA, Presa M, Díez JL, Solano C, Moraleda JM, Caballero D

 

 

Axicabtagene ciloleucel for the management of patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma: an economic evaluation for Spain
25th European Hematology Association Congress. Virtual. 11-14 jun 2020

Sierra J, Mareque M, Montesinos P, Guinea JM, Font P, Oyagüez I, Brockbank J, Candini D, Llinares J, Soto J, De La Fuente A

 

 

Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain
25th European Hematology Association Congress. Virtual. 11-14 jun 2020

Ventayol P, Ríos Herranz E, Echave M, Oyagüez I, Sánchez R, Salvador J, González Díaz M

 

 

Coste-efectividad de la terapia con venetoclax y rituximab versus ibrutinib, en pacientes con Leucemia Linfocítica Crónica en recaída o refractarios
VII Congreso de Oncología Médica, Hematología y Farmacia Oncohematológica. «Tendiendo Puentes». Toledo. 28-30 nov 2019

García A, Domínguez-Hernández R, Casado MA

 

 

 

Economic evaluation of an electronic health record alert by age in primary care for the detection of patients with chronic hepatitis C
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019

POSTER

Taxonera C, de Andrés-Nogales F, García S, Sánchez-Guerrero A, Menchen B, Peral C, Cábez A, Gómez S, López A, Casado MÁ, Menchén L

 

 

Cost-effectiveness of Tofacitinib for the Treatment of Moderate-to-severe Ulcerative Colitis After Conventional Therapy in Spain
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019

POSTER

de Andrés-Nogales F, Gay-Pobes PR, Inês M, Polanco Sánchez C, Alves D, Oyagüez I

 

 

Cost-effectiveness analysis of apixaban versus edoxaban for stroke prevention in non-valvular atrial fibrilation Portuguese patients
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019

POSTER

Menchén L, de Andrés-Nogales F, García S, Sánchez-Guerrero A, Menchen B, Cábez A, Gómez S, López A, Casado MÁ, Peral C, Taxonera C

 

Cost-effectivenes of Tofacitinib for the Treatment of Moderate-to-severe Ulcerative Colitis After Biologic Failure or Intolerance in Spain
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019

POSTER